Venetoclax and Tocilizumab for the Treatment of Patients With Relapsed or Refractory t(11;14) Multiple Myeloma

PHASE1RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 19, 2022

Primary Completion Date

February 12, 2026

Study Completion Date

February 12, 2027

Conditions

Recurrent Plasma Cell MyelomaRefractory Plasma Cell Myeloma

Interventions

BIOLOGICAL

Tocilizumab

Given IV

DRUG

Venetoclax

Given PO

Trial Locations (1)

RECRUITING

Emory University Hospital/Winship Cancer Institute, Atlanta

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

Emory University

OTHER